Mira Pharmaceuticals Inc. has reported continued progress toward IND-enabling studies of its two lead preclinical programs, MIRA-55, an investigational oral nonopioid drug candidate for chronic inflammatory pain, and SKNY-1, an investigational oral drug candidate for obesity and addiction-related disorders.
Olix Pharmaceuticals Inc. has released preclinical data from a head-to-head study in obese nonhuman primates (NHPs) showing that OLX-501A, its ALK7-targeting obesity program, achieved greater visceral fat reduction relative to a globally developed comparator compound.
Torrey Pines Medicine (Shenzhen) Ltd. has completed an angel financing round as it advances next-generation ultralong-acting peptide therapeutics for metabolic diseases.
Ascletis Pharma Inc. has released preclinical data for ASC-37, a next-generation glucagon-like peptide 1 receptor (GLP-1R)/gastric inhibitory polypeptide receptor (GIPR)/glucagon receptor (GCGR) triple peptide agonist.
Neumora Therapeutics Inc. has reported preclinical toxicology results from NMRA-215, a potentially best-in-class, highly brain-penetrant, oral NLRP3 inhibitor in development for the treatment of obesity and cardiometabolic disease.
Ascletis Pharma Inc. has selected a fixed-dose combination of ASC-48, an oral small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) agonist, and ASC-30, an oral small-molecule glucagon-like peptide 1 receptor (GLP-1R) agonist, for clinical development for obesity.
Rani Therapeutics Holding Inc. has entered into a research and development collaboration with Pegbio Co. Ltd. to explore the delivery of multiple candidates from Pegbio’s obesity and metabolic disease pipeline using Rani’s proprietary Ranipill platform.
Mira Pharmaceuticals Inc. has reported results from preclinical studies evaluating an optimized oral formulation of SKNY-1, an oral drug candidate being developed for obesity and addiction-related disorders.
Ascletis Pharma Inc. has submitted two IND applications to the FDA for ASC-36 once-monthly injection and ASC-36_35 once-monthly injection co-formulation for the treatment of obesity.
Mwyngil Therapeutics Inc. has released promising in vivo proof-of-concept results from its GPR75 inverse agonist program, supporting the potential of GPR75 modulation as a differentiated therapeutic approach for obesity and cardiometabolic disease.
